Fibrosis sungsum tulang mangrupikeun panyakit kronis sél hématopoietik sungsum. Éta kauntungan tina ubar pangambat JAK2: relief gejala, salamet berkepanjangan, sareng ningkat kualitas hirup. Nanging, dua atanapi tilu taun saatos ngamimitian pangobatan, sababaraha pasien ngembangkeun limfoma B-sél agrésif. Dina kolaborasi deukeut jeung peneliti di Wina, MedUni na Vetmeduni, sambetan JAK2 awakened "dormant" lymphoma jeung kanker dina sungsum tulang pikeun kahiji kalina.
Using bone marrow biopsy at the beginning of the disease, 16% of patients with myelofibrosis were found to have dormant aggressive lymphoma. In about 6% of these patients, when stimulated with JAK2 inhibitors, it bursts. According to hematologists, if sensitive molecular biology techniques are used to actively search for latent lymphoma, it is possible to detect dormant lymphoma. This is the best predictive tool that allows us to screen out 16% of patients identified as high-risk patients before treatment with JAK2 inhibitors.
Éta kabuktosan dina modél beurit yén beurit anu ngalaman cangkok sungsum tulang ogé ngembangkeun limfoma. Kerjasama multilateral mangrupikeun conto anu saé kumaha panilitian umumna parantos kabuka sareng pentingna pertukaran data dina ubar. Léngkah salajengna: kumpulan kasus internasional sareng data anu aya hubunganana parantos mimiti ningkatkeun kasalametan narkoba, sareng panaliti damel caket sareng perusahaan farmasi anu ngahasilkeun ubar standar ieu. Ngadegkeun sasak gancang, épisién sareng groundbreaking antara modél beurit sareng pamanggihan klinis, sampurna ngagabungkeun panilitian dasar, padamelan préklinikal sareng klinis pikeun nguntungkeun penderita kanker.
